// App-Quantinova.ai

TPS4145 : Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial.

Researchers

Presenter

  • Thomas Jens Ettrich

Principal Investigators

  • Andreas Wolfgang Berger

  • Thomas Seufferlein

  • Lukas Perkhofer

Medical Centers

  • Ulm University, Ulm, Germany

  • Ulm University, Department of Internal Medicine I, Ulm, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating DNA

Drug/Treatment

  • Irinotecan

  • Adrucil injection

  • Fluorouracil

  • Gemcitabine

  • leucovorin

  • Cisplatin

Outcome

  • Indeterminate

Study Design

  • Randomized

  • Open Label

  • Non-Comparative

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03044587

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved